Reduced CREB3L2 expression is associated with resistance to sorafenib and poor prognosis in ER-positive breast cancer
Sean Mullarkey, Vahid Arabkari, Muhammad Mosaraf Hossain, Sanjeev Gupta, Ananya Gupta
The paper identifies CREB3L2 expression as a biomarker for sorafenib response and poor prognosis in ER-positive breast cancer.
bioRxiv · Oct 3, 2016 · PreprintCancer Biology